• InterView
• AstraZeneca seeks mutual growth through open collaboration
• by Hwang, Byung-woo Aug 27, 2024 05:50am

• Company
• More urothelial cancer drug options now available in KOR
• by Hwang, Byung-woo Aug 26, 2024 05:46am

• Company
• ‘Lilly will reapply for Retevmo’s reimbursement in Korea’
• by Eo, Yun-Ho Aug 26, 2024 05:46am

• Policy
• Eliquis generics re-enter the market, 35 reimbursed drugs
• by Lee, Tak-Sun Aug 26, 2024 05:46am

• Company
• Colorectal cancer drug Fruzaqla may be introduced in H2
• by Eo, Yun-Ho Aug 26, 2024 05:46am

• Policy
• Hanmi faces competition from cheaper Zytiga generic drug
• by Lee, Tak-Sun Aug 26, 2024 05:45am

• Company
• Expansion of newly launched Kerendia underway in KOR
• by Moon, sung-ho Aug 23, 2024 06:18am

• Opinion
• [Reporter’s View]Gov’t disappointing response to COVID-19
• by Son, Hyung-Min Aug 23, 2024 06:18am

• Company
• Will the SGLT-2i Jardiance be reimb for CKD in 2H?
• by Eo, Yun-Ho Aug 23, 2024 06:18am

• Policy
• DREC to review the COVID-19 drug Paxlovid a week earlier
• by Lee, Tak-Sun Aug 23, 2024 06:17am